Evotec SE ADR (EVO)

Evotec SE ADR is a depositary receipt representing common stock of Evotec SE and is listed on NASDAQ under the symbol EVO. Evotec SE is a drug discovery and development company with operations in the United States, Germany, France, the United Kingdom, Switzerland, and other international markets. The company is organized around two segments, Shared R&D and Just - Evotec Biologics, and works on pharmaceutical programs across a broad set of therapeutic areas, including oncology, autoimmune and inflammatory conditions, diabetes, heart failure, infectious diseases, kidney and liver disorders, respiratory and fibrotic diseases, metabolic disease, rare diseases, and central nervous system and cardiometabolic conditions. It also has programs related to animal and women’s health. Evotec collaborates with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capital partners, and has agreements with organizations including Mass General Brigham, Joslin Diabetes Center, BMS, Novo Nordisk, the University of Oxford, and several other research institutions. The company was founded in 1993 and is headquartered in Hamburg, Germany.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.